NCT05957978 - LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

June 27, 2025

Study Completion Date

November 26, 2025

Conditions

Primary Visceral Leishmaniasis

Interventions

DRUG

LXE408

Film-coated tablets

DRUG

sodium stibogluconate

Dosage/Administration: sodium stibogluconate 20 mg/kg/day intravenous/intramuscular (IV/IM) q.d.

DRUG

Paromomycin

Dosage/Administration: paromomycin 15 mg/kg/day IM q.d.

Trial Locations (1)

University of Gondar, Gonder